Physician profile
Leonard A Pace
NPI 1639110620
$4,700.71
in general payments reported to CMS, 2019-2025
29 companies · $838 in 2025
The $838 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $810 · 2021: $926 · 2022: $408 · 2023: $451 · 2024: $537 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $901.10 | 2019-2025 | |
| Ucb, INC. | $729.67 | 2019-2023 | Briviact |
| Lilly USA, LLC | $430.00 | 2019-2025 | Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $327.87 | 2023-2025 | Rytary, Crexont |
| Otsuka America Pharmaceutical, INC. | $306.95 | 2023-2025 | Rexulti |
| Abbvie INC. | $267.27 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $218.76 | 2019-2024 | Amvuttra |
| Biogen, INC. | $217.82 | 2019-2025 | Leqembi |
| Emd Serono, INC. | $156.97 | 2019-2020 | |
| Ge Healthcare | $134.15 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $129.85 | 2020-2021 | |
| Amgen INC. | $103.35 | 2019-2025 | Uplizna |
| Pfizer INC. | $96.84 | 2021-2025 | |
| Adamas Pharmaceuticals, INC. | $79.87 | 2020-2021 | |
| Avion Pharmaceuticals | $70.11 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $64.53 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $63.21 | 2019-2024 | Austedo Xr |
| Allergan, INC. | $59.43 | 2019-2020 | |
| Medtronic, INC. | $59.33 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $46.62 | 2021-2025 | Nuplazid |
| Sk Life Science, INC. | $45.84 | 2021 | |
| Celgene Corporation | $41.05 | 2021-2022 | |
| Banner Life Sciences, LLC | $40.36 | 2021 | |
| Neurocrine Biosciences, INC. | $34.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.54 | 2022 | |
| Boston Scientific Corporation | $17.77 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $16.36 | 2021 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 | |
| Forte Bio-Pharma LLC | $10.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.